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a b s t r a c t
Conformational dynamics of wild-type human butyrylcholinesterase (BChE), two mutants of residue
Ala328, the catalytically active Ala328Cys, and the catalytically inactive (silent) Ala328Asp, and their
interactions with butyrylcholine were studied. The aim was to understand the molecular mechanisms by
which point mutations may lead to silent BChE variant or alter catalytic activity. Importance of BChE
natural variants is due to medical consequences, i.e. prolonged apnea, following administration of the
myorelaxant esters, succinylcholine and mivacurium.
Comparison of molecular dynamics (MD) simulations for the three model systems showed that: 1) the
active mutant Ala328Cys mutant has some changes in conﬁguration of catalytic residues, which do not
prevent binding of butyrylcholine to the active site; 2) in the naturally-occurring silent variant
Ala328Asp, the Asp328 carboxylate may either form a salt bridge with Lys339 or a H-bond with His438.
In the ﬁrst case, the U-loop swings off the gorge, disrupting the p-cation binding site and the catalytic
triad. In the second case, binding of cationic substrates in the catalytic center is also impaired. MD
simulations carried out in 0.15 M NaCl, close to physiological ionic strength conditions, favored the
second situation. It was seen that Asp328 forms a H-bond with the catalytic triad His438, which in turn
disrupts the catalytic machinery. Therefore, we concluded that the Ala328Asp variant is not catalytically
active because of that dramatic event. Computational results, consistent with in vitro biochemical data
and clinical observations, validate our MD approach.
© 2016 Elsevier Ireland Ltd. All rights reserved.
1. Introduction
Human butyrylcholinesterase (BChE, EC. 3.1.1.8) is a sialoglyco-
proteinwhose 3D structure is similar to that of acetylcholinesterase
(AChE, EC. 3.1.1.7) [1]. The BChE monomer is composed of 574
amino acids. BChE is present in numerous tissues and plasma
where its concentration is about 50 nM. The tetrameric form is the
major component of the human plasma BChE [2]. Unlike AChE that
plays a key role in the cholinergic system in terminating the action
of the neurotransmitter acetylcholine, BChE has no clear physio-
logical functions. However, BChE hydrolyzes numerous carboxyl-
esters and reacts with carbamyl- and phosphyl-esters (progres-
sive inhibition). Thus, BChE is of pharmacological and toxicological
importance. In particular the plasma enzyme, plays a role in
catabolism of ester-containing drugs (e.g. succinylcholine, miva-
curium, aspirin) and poisonous esters (e.g. cocaine, heroin), xeno-
biotics (e.g. carbamate pesticides, organophosphate pesticides,
cresylsaligenin phosphate d the active metabolite of the ﬂame
retardant tri-o-cresylphosphate, and chemical warfare nerve
Abbreviations: AChE, acetylcholinesterase; BCh, butyrylcholine; BCHE, butyr-
ylcholinesterase gene; BChE, butyrylcholinesterase enzyme; EDA, essential dy-
namics analysis; H-bond, hydrogen bond; MD, molecular dynamics; PAS, peripheral
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steered, molecular dynamics; US, umbrella sampling; wt, wild type.
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